- These studies combined with new digital tools aim to increase access and frequency of hereditary cancer screening both before and during treatment - SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- ...
– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results